natgillin/translations-raw huggingface dataset:
Visually inspect the contents of each Optaflu syringe for particulate matter and/or change in colour prior to administration.
Vsebino vsake brizge cepiva Optaflu pred uporabo vizualno preglejte in se prepričajte, da v njej ni delcev in da barva ni spremenjena.
Sodium chloride, potassium chloride, magnesium chloride hexahydrate, disodium phosphate dihydrate, potassium dihydrogen phosphate and water for injections.
Natrijev klorid, kalijev klorid, magnezijev klorid heksahidrat, natrijev hidrogenfosfat dihidrat, kalijev
Optaflu is a vaccine against flu (influenza).
Kaj je cepivo OPTAFLU in za kaj ga uporabljamo Optaflu je cepivo proti gripi (influenci).
So far there is limited post-marketing experience with Optaflu.
Izkušnje s cepivom Optaflu v obdobju trženja so omejene.
Vaccine efficacies against vaccine-matched influenza viral strains, against all influenza viral strains, and against individual influenza viral subtypes were
Izračunali so učinkovitost cepiva proti sevom virusa gripe, ki so se ujemali s cepilnimi sevi, proti vsem sevom virusa gripe in posameznim podtipom virusa gripe (preglednici 2 in 3).
Very rare (affects less than 1 user in 10,000): • skin rashes, fever, joint pain or kidney problems which are symptoms of an inflammation of the
Zelo redki (pojavijo se pri manj kot 1 od 10.000 cepljenih): • kožni izpuščaji, zvišana telesna temperatura, bolečina v sklepih ali težave z ledvicami,
• weakness beginning in the legs and progressing to the arms with numbness and tingling sensation which are symptoms of an inflammation of the nerves
• šibkost, ki se začenja v nogah in napreduje v roke, z otrplostjo in mravljinčenjem, ki so
The vaccine complies with the WHO recommendation (northern hemisphere) and EU decision for
Cepivo je v skladu s priporočili SZO (za severno poloblo) in z odločbo EU za sezono 2015/2016.
10 pre-filled syringes with needle.
10 napolnjenih injekcijskih brizg z iglo.
- Extensive swelling of injected limb
- Obsežno otekanje uda, v katerega je bilo injicirano cepivo
Organ class
Organski sistem
Optaflu was well tolerated and immunogenic in mice and ferrets.
Cepivo Optaflu so miši in beli dihurji dobro prenašali in pri njih je bilo imunogeno.
Hypersensitivity to the active substances or to any of the excipients listed in section 6.1.
Preobčutljivost na zdravilne učinkovine ali katero koli pomožno snov.
Very common (affects more than 1 user in 10):
Zelo pogosti (pojavijo se pri več kot 1 od 10 cepljenih):
What Optaflu looks like and contents of the pack Optaflu is a suspension for injection in a pre-filled syringe (ready-to-use syringe).
Cepivo Optaflu je suspenzija za injiciranje v napolnjeni injekcijski brizgi (brizga, pripravljena za uporabo).
Optaflu suspension for injection in a pre-filled syringe Influenza vaccine (surface antigen, inactivated, prepared in cell cultures)
Optaflu suspenzija za injiciranje v napolnjeni injekcijski brizgi cepivo proti gripi iz kulture celic, s površinskimi antigeni, inaktivirano
1 pre-filled syringe (0.5 ml) with needle 10 pre-filled syringes (0.5 ml) with needle 1 pre-filled syringe (0.5 ml) without needle 10 pre-filled syringes (0.5 ml) without needle
1 napolnjena injekcijska brizga (0,5 ml) z iglo 10 napolnjenih injekcijskih brizg (0,5 ml) z iglo 1 napolnjena injekcijska brizga (0,5 ml) brez igle 10 napolnjenih injekcijskih brizg (0,5 ml) brez igle
PARTICULARS TO APPEAR ON THE OUTER PACKAGING MULTIPACK - Outer carton box for containing 2 carton boxes with 10 syringes each (with or without needles)
VEČKRATNO PAKIRANJE - Zunanja kartonska škatla, ki vsebuje 2 kartonski škatli s po 10 injekcijskimi brizgami
The active substances are influenza virus surface antigens (haemagglutinin and neuraminidase)*, inactivated, of the following strains:
Zdravilne učinkovine so površinski antigeni virusa influence (hemaglutinin in nevraminidaza)*,
Not known (cannot be estimated from the available data) • swelling most apparent in the head and neck, including the face, lips, tongue, throat or any other
• otekanje, ki je najbolj izrazito na glavi in vratu, lahko pa zajame obraz, ustnice, jezik, žrelo in kateri koli drug del telesa (angioedem).
QUALITATIVE AND QUANTITATIVE COMPOSITION Influenza virus surface antigens (haemagglutinin and neuraminidase)*, inactivated, of the following
KAKOVOSTNA IN KOLIČINSKA SESTAVA Sevi virusa influence s površinskimi antigeni (hemaglutinin in nevraminidaza)*, inaktivirani: Sevu A/California/7/2009 (H1N1)pdm09 podoben sev
Carton box for syringe(s) without needle - 1 pre-filled syringe (0.5 ml) without needle - 10 pre-filled syringes (0.5 ml) without needle
Kartonska škatla za brizgo/brizge brez igle - 1 napolnjena injekcijska brizga (0,5 ml) brez igle - 10 napolnjenih injekcijskih brizg (0,5 ml) brez igle
Carton Box for syringe(s) with needle - 1 pre-filled syringe (0.5 ml) with needle - 10 pre-filled syringes (0.5 ml) with needle
Kartonska škatla za brizgo/brizge z iglo - 1 napolnjena injekcijska brizga (0,5 ml) z iglo - 10 napolnjenih injekcijskih brizg (0,5 ml) z iglo
Adults from the age of 18 years:
Odrasli od starosti 18 let: En odmerek 0,5 ml
Table 3: Comparative Efficacy of Optaflu versus Placebo against Culture-Confirmed
Preglednica 3: Primerjava učinkovitosti cepiva Optaflu in placeba proti laboratorijsko potrjeni gripi po posameznih podtipih virusa gripe
No evidence of reproductive or developmental toxicity was seen in a study where the human dose of Optaflu was administered prior to and during gestatioin to female rabbits.
V študiji, v kateri so odmerek cepiva Optaflu za ljudi dajali samicam kuncev pred brejostjo in med njo, niso našli dokazov za učinke na sposobnost razmnoževanja ali razvoja.
Keep the pre-filled syringe in the outer carton in order to protect
Napolnjeno injekcijsko brizgo shranjujte v zunanji škatli za
5.3 Preclinical safety data
6.4 Posebna navodila za shranjevanje
PARTICULARS TO APPEAR ON THE OUTER PACKAGING
Izgled cepiva Optaflu in vsebina pakiranja
If either condition exists, do not administer the vaccine.
Ne uporabite cepiva, če kar koli opazite.
PHARMACOLOGICAL PROPERTIES
IMETNIK DOVOLJENJA ZA PROMET Z ZDRAVILOM
The following additional adverse reactions were reported from post-marketing surveillance with
Iz spremljanja v obdobju trženja so poročali o naslednjih dodatnih neželenih učinkih s sezonskimi trivalentnimi cepivi na osnovi jajc:
MARKETING AUTHORISATION HOLDER
ŠTEVILKA (ŠTEVILKE) DOVOLJENJA (DOVOLJENJ) ZA PROMET
Keep this vaccine out of the sight and reach of children.
Zdravilo shranjujte nedosegljivo otrokom!
It is available as tablets (1 and 2 mg).
Na voljo je v obliki tablet (1 in 2 mg).
The European Commission granted a marketing authorisation valid throughout the European Union for Resolor on 15 October 2009.
Evropska komisija je dovoljenje za promet z zdravilom Resolor, veljavno po vsej Evropski uniji, izdala 15. oktobra 2009.
What measures are being taken to ensure the safe and effective use of Resolor?
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Resolor?
The full EPAR for Resolor can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Resolor je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
What benefit has Resolor shown during the studies?
Kakšne koristi je zdravilo Resolor izkazalo med študijami?
A risk management plan has been developed to ensure that Resolor is used as safely as possible.
Za zagotovitev čim varnejše uporabe zdravila Resolor je bil pripravljen načrt obvladovanja tveganj.
This is a summary of the European public assessment report (EPAR) for Resolor.
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Resolor.
Other information about Resolor
Druge informacije o zdravilu Resolor
For more information about treatment with Resolor, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Za več informacij o zdravljenju z zdravilom Resolor preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
The patients had not responded well enough to previous treatment with laxatives.
Bolniki se niso zadostno odzvali na predhodna zdravljenja z odvajali.
It must also not be used in patients with intestinal perforation or obstruction, severe inflammatory conditions of the intestines such as Crohn's disease, ulcerative colitis (inflammation of the large intestine causing ulceration and bleeding) and toxic megacolon and megarectum (very serious complications of colitis).
Ne sme se uporabljati niti pri bolnikih s perforacijo ali zaporo črevesja, hudimi vnetnimi stanji črevesja, kot je Crohnova bolezen, ulcerativnim kolitisom (vnetjem debelega črevesja, ki povzroči razjede in krvavitve) in toksičnim megakolonom in megarektumom (zelo hudim zapletom kolitisa).
This means that it works like a substance in the body called 5-hydroxytryptamine (5-HT, also known as serotonin) and attaches to receptors for 5-HT in the gut called ‘5-HT4 receptors'.
To pomeni, da deluje enako kot snov v telesu, imenovana 5-hidroksitriptamin (5-HT, znana tudi kot serotonin), in se veže na iste receptorje v črevesju, imenovane receptorji 5-HT4.
The result from patients who received Resolor at the higher dose of 4 mg was similar to those who took the 2 mg dose.
Rezultati pri bolnikih, ki so jemali višji 4-miligramski odmerek, so bili podobni kot pri tistih, ki so jemali 2-miligramski odmerek.
The CHMP decided that Resolor's benefits are greater than its risks and recommended that it be given marketing authorisation..
CHMP je zaključil, da so koristi zdravila Resolor večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Resolor.
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil to zdravilo, na podlagi česar je oblikoval mnenje za izdajo dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
Resolor was more effective than placebo at treating chronic constipation.
Zdravilo Resolor je bilo pri zdravljenju kroničnega zaprtja učinkovitejše od placeba.
What is the risk associated with Resolor?
Kakšna tveganja so povezana z zdravilom Resolor?
Resolor is a medicine that contains the active substance prucalopride.
Resolor je zdravilo, ki vsebuje zdravilno učinkovino prukaloprid.
The main measure of effectiveness in the studies was the number of patients who completely emptied their bowels at least three times a week over a 12 week period without the help of laxatives.
Glavno merilo učinkovitosti v vseh študijah je bilo število bolnikov, ki so vsaj trikrat na teden v 12-tedenskem obdobju popolnoma izpraznili črevesje brez pomoči odvajal.
In the same way, when prucalopride attaches to and stimulates these receptors, it increases this movement and allows the bowels to empty faster.
Prukaloprid se na enak način veže na te receptorje in jih spodbudi ter tako poveča dejavnost črevesja in mu pomaga, da se hitreje izprazni.
The most common side effects with Resolor (seen in more than 1 patient in 10) are headache, nausea (feeling sick), diarrhoea and abdominal (tummy) pain.
Najpogostejši neželeni učinki zdravila Resolor (opaženi pri več kot 1 bolniku od 10) so glavobol, navzeja (siljenje na bruhanje), driska in bolečine v trebuhu.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Resolor, including the appropriate precautions to be followed by healthcare professionals and patients.
V skladu z njim so bile v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
When 5-HT binds to these receptors, it normally stimulates movement in the gut.
Pri vezavi na te receptorje 5-HT običajno spodbudi dejavnost črevesja.
The active substance in Resolor, prucalopride, is a ‘5-HT4 receptor agonist'.
Zdravilna učinkovina v zdravilu Resolor, prukaloprid, je agonist za receptor 5-HT4.
Resolor must not be used in patients with kidney problems requiring dialysis (a blood clearance technique).
Zdravilo Resolor se ne sme uporabljati pri bolnikih, ki imajo obolenje ledvic, pri katerem je potrebna dializa (tehnika čiščenja krvi).
Resolor is used to treat symptoms of chronic (long-term) constipation in adults for whom laxatives (medicines that trigger bowel movements) do not work well enough.
Zdravilo Resolor se uporablja za zdravljenje simptomov kroničnega (dolgotrajnega) zaprtja pri odraslih, pri katerih odvajala (zdravila, ki pospešijo delovanje črevesja) ne delujejo dovolj dobro.
Over the 12-week period, 24% (151 out of 640) of patients who received Resolor 2 mg completely emptied their bowels at least three times a week, compared with 11% (73 out of 645) of patients who received placebo.
V 12-tedenskem obdobju je 24 % (151 od 640) bolnikov, ki so prejemali 2 mg zdravila Resolor, popolnoma izpraznilo svoje črevesje vsaj trikrat na teden, v primerjavi z 11 % (73 od 645) bolnikov, ki so prejemali placebo.
Why has Resolor been approved?
Zakaj je bilo zdravilo Resolor odobreno?
Patients aged over 65 years should start with a 1 mg dose once a day, and this can be increased to 2 mg once a day if needed.
Priporočeni odmerek zdravila Resolor je 2 mg enkrat na dan. Bolniki, starejši od 65 let, naj začnejo z 1-miligramskim odmerkom enkrat na dan, po potrebi pa se lahko odmerek zviša na 2 mg enkrat na dan.
For the full list of all side effects reported with Resolor, see the package leaflet.
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Resolor, glejte navodilo za uporabo.
In the study of men with chronic constipation, 38% of patients treated with Resolor 2 mg (67 out of 177) completely emptied their bowels at least three times a week, compared with 18% of those given placebo (32 out of 181).
V študiji, v kateri so sodelovali moški s kroničnim zaprtjem, je 38 % (67 od 177) bolnikov, zdravljenih z zdravilom Resolor v odmerku 2 mg, uspelo najmanj trikrat tedensko popolnoma izprazniti črevesje v primerjavi z 18 % (32 od 181) bolnikov, ki so prejemali placebo.
Resolor 2 mg once a day was also compared with placebo in another main study involving 374 men with chronic constipation.
V drugi glavni študiji so zdravilo Resolor v odmerku 2 mg enkrat na dan primerjali s placebom pri 374 moških s kroničnim zaprtjem.
How has Resolor been studied?
Kako je bilo zdravilo Resolor raziskano?
What is Resolor used for?
Za kaj se zdravilo Resolor uporablja?
How is Resolor used?
Kako se zdravilo Resolor uporablja?
What is Resolor?
Kaj je zdravilo Resolor?
Resolor (2 or 4 mg once a day) was compared with placebo (a dummy treatment) in three main studies involving 1,999 patients with chronic constipation, 88% of whom were women.
V treh glavnih študijah, v katerih je sodelovalo 1 999 bolnikov s kroničnim zaprtjem, med katerimi je bilo 88 % žensk, so zdravilo Resolor (2 ali 4 mg enkrat na dan) primerjali s placebom (zdravilom brez zdravilne učinkovine).
How does Resolor work?
Kako zdravilo Resolor deluje?
Strength Pharmaceutical Form Route of Administration Packaging
Farmacevtska oblika Pot uporabe
ATCvet code: QC03CA04.
Koda ATCvet: QC03CA04.
The plasma protein binding was > 98%.
Vezava na plazemske beljakovine je znašala > 98 %.
10 DATE OF REVISION OF THE TEXT {DD/MM/YYYY}
10 DATUM REVIZIJE BESEDILA {DD/MM/LLLL}
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 31/07/2015
DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJA ZA PROMET Datum prve odobritve: 31/07/2015
Refer to section 4.5.
Glejte poglavje 4.5.
QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains:
KAKOVOSTNA IN KOLIČINSKA SESTAVA Vsaka tableta vsebuje:
MARKETING AUTHORISATION NUMBER(S) EU/2/15/184/001-008
ŠTEVILKA DOVOLJENJA/ŠTEVILKE DOVOLJENJ ZA PROMET EU/2/15/184/001-008
A large proportion of the dose (between 61% and 70%) is excreted in the urine as unchanged parent drug.
Velik delež odmerka (med 61 % in 70 %) se izloči z urinom kot nespremenjeno matično zdravilo.
Doses greater than 0.8 mg/kg/day have not been evaluated in the target animal safety or controlled clinical studies.
Odmerki, večji od 0,8 mg/kg/dan, niso bili ovrednoteni pri varnosti ciljne živali ali kontroliranih kliničnih študijah.
While the animal is on treatment, these parameters should be monitored at very regular intervals according to the benefit-risk assessment performed by the responsible veterinarian.
Medtem ko žival dobiva zdravilo, je te parametre treba spremljati v zelo rednih časovnih presledkih v skladu z oceno koristi in tveganj, ki jo opravi pristojni veterinar.
This in turn decreases free water reabsorption resulting in increased water excretion/urine production.
To pa zmanjšuje prosto reabsorpcijo vode, kar povzroči povečano izločanje vode/nastajanje urina.
Any part tablet should be stored in the blister pack or in a closed container for a maximum of 7 days.
Vsak del tablete je treba shranjevati v pretisnem omotu ali v zaprtem vsebniku, in to največ 7 dni.
18 mg of torasemide For the full list of excipients, see section 6.1.
18 mg torasemida Za celoten seznam pomožnih snovi glejte poglavje 6.1.
The daily schedule of administration can be timed to control the period of micturition according to need.
Dnevno shemo dajanja lahko načrtujemo tako, da nadzorujemo obdobje uriniranja po potrebi.
Once signs of congestive heart failure have been controlled and the patient is stable, if long term diuretic therapy with this product is required it should be continued at the lowest effective dose.
Ko so znaki kongestivnega srčnega popuščanja nadzorovani in je bolnik stabilen, je v primeru potrebe po dolgotrajnem diuretičnem zdravljenju s tem izdelkom treba nadaljevati z najnižjim učinkovitim odmerkom.
Vétoquinol SA Magny-Vernois 70200 Lure FRANCE
Vétoquinol SA Magny-Vernois 70200 Lure FRANCIJA
Feeding significantly increased torasemide AUClast by 36% on average and slightly delayed Tmax but no significant impact on Cmax was detected.
Hranjenje je znatno povečalo AUClast torasemida v povprečju za 36 % in rahlo upočasnilo Tmax, vendar ni bilo zaznanega pomembnega vpliva na Cmax.
Any remaining tablet part should be discarded after 7 days.
Neporabljeni del tablete je treba zavreči po 7 dneh.
Frequent re-examinations of the dog will enhance the establishment of an appropriate diuretic dose.
Pogosti ponovni pregledi psa bodo pripomogli k vzpostavitviv ustreznega odmerka diuretika.
If you notice any serious effects or other effects not mentioned in this package leaflet, please inform your veterinary surgeon.
Če opazite kakršne koli resne stranske učinke ali druge učinke, ki niso omenjeni v teh navodilih za uporabo, obvestite veterinarja.
Loop diuretics mainly inhibit the Na+/2Cl-/K+ carrier from the luminal side of the cell.
Diuretiki zanke predvsem zavirajo nosilec za Na+/2Cl-/K+ na luminalni strani celice.
4.4 Special warnings for each target species None.
Posebna opozorila za vsako ciljno živalsko vrsto Jih ni.
The use of UpCard is not recommended during pregnancy, lactation and in breeding animals.
Uporaba zdravila UpCard ni priporočena v obdobju brejosti, laktacije in pri vzrejnih živalih.
Disposal: read package leaflet.
Odstranjevanje: preberite navodila za uporabo.
EU/2/15/184/001 30 tablets of 0.75 mg EU/2/15/184/002 100 tablets of 0.75 mg EU/2/15/184/003 30 tablets of 3 mg EU/2/15/184/004 100 tablets of 3 mg EU/2/15/184/005 30 tablets of 7.5 mg EU/2/15/184/006 100 tablets of 7.5 mg EU/2/15/184/007 30 tablets of 18 mg EU/2/15/184/008 100 tablets of 18 mg
EU/2/15/184/001 30 tablet po 0,75 mg EU/2/15/184/002 100 tablet po 0,75 mg EU/2/15/184/003 30 tablet po 3 mg EU/2/15/184/004 100 tablet po 3 mg EU/2/15/184/005 30 tablet po 7,5 mg EU/2/15/184/006 100 tablet po 7,5 mg EU/2/15/184/007 30 tablet po 18 mg EU/2/15/184/008 100 tablet po 18 mg
As a result of the diuretic action of torasemide, haemoconcentration and, very commonly, polyuria and/or polydipsia are observed.
Kot rezultat diuretičnega delovanja torasemida je bila opažena hemokoncentracija in zelo pogosto poliurija in/ali polidipsija.
All strengths are available in the following pack sizes: Pack sizes of 30 or 100 tablets.
Vse jakosti so na voljo v naslednjih pakiranjih: Velikosti pakiranja 30 ali 100 tablet.
Occurrence of soft faeces is transient, mild, and does not necessitate the withdrawal of the treatment.
Pojav mehkega blata je prehoden, blag in ne zahteva prekinitve zdravljenja.
In case of accidental ingestion, particularly in the case of children, seek medical advice immediately and show the package leaflet or the label to the physician.
V primeru nenamernega zaužitja, posebej pri otrocih, takoj poiščite zdravniško pomoč in pokažite navodilo za uporabo ali nalepko zdravniku.
Do not use in case of severe dehydration, hypovolaemia or hypotension.
Ne uporabite v primeru hude dehidracije, hipovolemije ali hipotenzije.
Polychlorotrifluoroethylene-PVC/aluminium blister pack (each blister pack contains 10 tablets) and is packaged in an outer cardboard box.
Poliklortrifluoretilen-PVC/aluminijev pretisni omot (vsak pretisni omot vsebuje 10 tablet) je pakiran v zunanji kartonasti škatli.
In dogs with pre-existing electrolyte and/or water imbalance, this should be corrected prior to treatment with torasemide.
Pri psih z pred-obstoječim neravnovesjem elektrolitov in/ali vode bi bilo to treba popraviti pred začetkom zdravljenja s torasemidom.
However, it is anticipated that overdose increases the risk of dehydration, electrolyte imbalance, renal insufficiency, anorexia, weight loss and cardiovascular collapse.
Vendar pa je pričakovati, da prevelik odmerek poveča tveganje za dehidracijo, elektrolitsko neravnovesje, ledvično insuficienco, anoreksijo, hujšanje in kardiovaskularni kolaps.
Torasemide can reduce the renal excretion of salicylates, leading to an increased risk of toxicity.
Torasemid lahko zmanjša ledvično izločanje salicilatov, kar vodi v povečano tveganje za toksičnost.
OTHER INFORMATION
DRUGI PODATKI
BATCH NUMBER Lot{number}
ŠTEVILKA SERIJE Lot{številka}
Concomitant use with veterinary medicinal products affecting electrolyte balance (corticosteroids, amphotericin B, cardiac glycosides, other diuretics) requires careful monitoring.
Sočasna uporaba veterinarskih zdravil, ki vplivajo na elektrolitsko ravnovesje (kortikosteroidi, amfotericin B, srčni glikozidi, drugi diuretiki), zahteva skrbno spremljanje.
DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED Detailed information on this product is available on the website of the European Medicines Agency (http://www.ema.europa.eu/).
DATUM ZADNJE ODOBRITVE NAVODIL ZA UPORABO Podrobne informacije o tem zdravilu za uporabo v veterinarski medicini so na voljo na spletni strani Evropske agencije za zdravila (European Medicines Agency) (http://www.ema.europa.eu/).
Torasemide may increase the risk of sulfonamide allergy.
Torasemid lahko poveča tveganje za alergijo na sulfonamid.
Medicines should not be disposed of via wastewater or household waste.
Zdravila ne odvrzite v odpadno vodo ali med gospodinjske odpadke.
This product may cause increased urination and/or gastrointestinal disturbances if ingested.
Ta izdelek lahko ob zaužitju povzroči povečano uriniranje in/ali prebavne motnje.
The tablets can be divided into equal halves.
Tablete lahko razpolovimo na enaki polovici.
Gastrointestinal signs which include emesis, reduced or absent faeces and, in rare cases, soft faeces may be observed.
Pojavijo se lahko gastrointestinalni znaki, ki vključujejo bruhanje, zmanjšano ali odsotno odvajanje blata, v redkih primerih se lahko pojavi mehko blato.